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Abstract The RAS pathway is central to epidermal homeostasis, and its activation in tumors or in
Rasopathies correlates with hyperproliferation. Downstream of RAS, RAF kinases are actionable
targets regulating keratinocyte turnover; however, chemical RAF inhibitors paradoxically activate
the pathway, promoting epidermal proliferation. We generated mice with compound epidermis-
restricted BRAF/RAF1 ablation. In these animals, transient barrier defects and production of
chemokines and Th2-type cytokines by keratinocytes cause a disease akin to human atopic
dermatitis, characterized by IgE responses and local and systemic inflammation. Mechanistically,
BRAF and RAF1 operate independently to balance MAPK signaling: BRAF promotes ERK activation,
while RAF1 dims stress kinase activation. In vivo, JNK inhibition prevents disease onset, while MEK/
ERK inhibition in mice lacking epidermal RAF1 phenocopies it. These results support a primary role
of keratinocytes in the pathogenesis of atopic dermatitis, and the animals lacking BRAF and RAF1
in the epidermis represent a useful model for this disease.
DOI: 10.7554/eLife.14012.001
Introduction
The largest organ of the body, the skin, allows exchange with the environment while shielding the
organism from insults of mechanical, chemical, and infectious nature. In the skin, the epidermis acts
as a mechanical barrier which prevents water loss and the entry of potentially harmful chemicals; in
addition, through the interplay between keratinocytes in the epidermis and immune cells based
mainly in the underlying dermis, the skin works as an immunological barrier actively defending the
body from pathogens (Pasparakis et al., 2014; Nestle et al., 2009). Maintaining these barrier func-
tions throughout life requires continuous regeneration of the epidermis and appropriately balanced
immune responses. Dysregulation of the regenerative process can lead to a wide range of defects,
from epidermal thickening to malignancies; and an imbalance in the skin’s immune reactions can
lead to recurrent infections, or inflammatory/allergic diseases such as psoriasis or atopic dermatitis.
The RAF/MEK/ERK signaling pathway plays an essential role in the epidermis. Downstream of the
EGFR and RAS, it acts in hair follicle development and wound healing; its mild activation in Rasopa-
thies, genetic diseases caused by activating mutations in the pathway, results in skin phenotypes
ranging from thickening of palms and soles to the development of papillomas; and strong activation
in keratinocytes results in tumorigenesis (Kern et al., 2011; Ratushny et al., 2012). In animal mod-
els, epidermis-restricted inducible activation of RAF or MEK causes massive cutaneous hyperplasia
and reduced differentiation (Khavari and Rinn, 2007). Consistently, RAF1 (also known as CRAF) and
BRAF are essential for the development and progression of RAS-induced tumors although they fulfil
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different roles, with RAF1 preventing keratinocyte differentiation (Ehrenreiter et al., 2009) and
BRAF promoting proliferation through MEK/ERK activation (Kern et al., 2013). The requirement for
MEK/ERK in epidermal proliferation has been independently assessed (Khavari and Rinn, 2007;
Dumesic et al., 2009; Scholl et al., 2009; Scholl et al., 2009).
In line with their prominent roles in cell proliferation and tumorigenesis in a number of tissues,
the components of the EGFR/RAS/RAF/MEK/ERK pathway are attractive targets for molecule-based
therapy. Many inhibitory compounds have been developed that are currently in clinical trials or have
reached the clinic. Reflecting the function of the pathway in skin, cutaneous toxicities are one of the
main adverse effects of these therapies; they can be severe and lead to an interruption of the ther-
apy or to its termination (Belum et al., 2013; Curry et al., 2014; Dy and Adjei, 2013). These
adverse effects can be roughly classified as inflammatory reactions, elicited chiefly by blocking EGFR
or MEK; and proliferative events, caused by multikinase inhibitors such as sorafenib or by more spe-
cific RAF inhibitors (vemurafenib, dabrafenib). Cutaneous inflammation induced by agents blocking
EGFR (erlotinib or cetuximab) and by MEK inhibitors (selumetinib and trametinib) is characterized by
papulopustular rash, pruritus, and suppurative folliculitis in 80% of the patients (Curry et al.,
2014). The effects of erlotinib and cetuximab are on-target, as recently demonstrated by two studies
showing similar inflammatory phenotypes in mice with epidermis-restricted EGFR ablation
(Mascia et al., 2013; Lichtenberger et al., 2013).
Skin rashes and pruritus are also observed in patients treated with inhibitors targeting RAF. Up to
half of the cutaneous reactions induced by these compounds, however, consist of anomalous epider-
mal proliferation events ranging from different forms of keratosis to the development of drug-
induced papillomas, keratoacanthomas, and squamous cell carcinomas (4–30% depending on the
study and the inhibitors used) (Anforth et al., 2013). These side effects are mechanism-based and
eLife digest The skin is the largest organ of the body and shields it from damage. It is also
home to cells of the immune system, which protect the body from infections. To maintain its role as
a barrier, the skin regenerates throughout life, constantly producing new cells to replace the old
ones. If this process goes wrong and the skin regenerates too much, the skin may produce tumors.
Likewise, disrupting the immune barrier can lead to autoimmune or allergic skin diseases such as
psoriasis or atopic dermatitis (also known as eczema).
The outer layer of the skin is called the epidermis, and is made up of cells known as
keratinocytes. A family of proteins called RAF plays an important role in controlling how
keratinocytes behave. These proteins are part of a signaling pathway that controls the production of
new cells and is disrupted in skin tumors. Therapies that inhibit RAF are effective treatments for
these tumors but have side effects that can affect the skin so severely that the treatment must be
interrupted.
Keratinocytes also play a role in the development of allergic skin diseases. However, it is not
known whether they do so by triggering the disease themselves, or by responding to stimuli
produced by immune cells.
Raguz et al. investigated what would happen if RAF proteins were removed from keratinocytes in
the epidermis of mice. This caused the mice to develop an allergic disease similar to human atopic
dermatitis. This was an unexpected effect and different from the side effects caused by drugs that
inhibit RAF proteins. By analyzing the signaling pathway that RAF is part of, Raguz et al. discovered
that removing RAF from the epidermis reduces the pathway’s ability to prevent excessive stress
signals being sent throughout the skin. Under these conditions, the keratinocytes bring about
inflammation and allergy by activating the immune cells in the skin and elsewhere.
Overall, the results presented by Raguz et al. indicate that allergic dermatitis can be triggered by
defects in keratinocytes rather than in immune cells. Furthermore, RAF in the epidermis appears to
prevent allergic skin diseases. Future studies could use mice that lack RAF in their epidermis to
further understand atopic dermatitis and to investigate the way in which drugs that target RAF can
damage the skin.
DOI: 10.7554/eLife.14012.002
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rely on the paradoxical activation of MEK/ERK promoted by the inhibitors in cultured cells, animal
models, and patients (Samatar and Poulikakos, 2014; Holderfield et al., 2014). Consistent with
this, combination treatment (RAF plus MEK inhibitors) reduces cutaneous toxicity (Flaherty et al.,
2012; Mattei et al., 2013).
In contrast to RAF inhibitor treatment, inducible epidermis-restricted ablation of BRAF and RAF1
causes the rapid regression of RAS-driven tumors without apparent cutaneous toxicity (Kern et al.,
2013). Here, we systematically test the effect of compound BRAF/RAF1 ablation in epidermis and
show that it gives rise to a progressive disease strongly resembling human atopic dermatitis. Mecha-
nistically, the disease relies on the combination of reduced ERK and increased stress kinase activa-
tion, leading to chemokine/cytokine overproduction and chronic, systemic inflammation.
Results
Epidermal BRAF and RAF1 are essential to prevent local and systemic
inflammation
BRAF and RAF1 were ablated in the epidermis by introducing the Krt5-Cre transgene
(Tarutani et al., 1997) into a Braf f/f; Raf1f/f background (Kern et al., 2013) (Figure 1A). The mice
(heretofore referred to as D/Dep2) were born at Mendelian ratio but with their eyes open
(Figure 1B), probably as a result of the migration defects of RAF1-deficient keratinocytes
(Ehrenreiter et al., 2005). With time, however, they started to show symptoms of a progressive skin
disease. These included intense itching and scratching resulting in partial alopecia and self-inflicted
wounds (Figure 1B). Histological examination of the non-affected areas revealed thickening of the
epidermis correlated with increased proliferation and expansion of both the basal and suprabasal
keratinocytes but not with keratinocyte apoptosis (Figure 1C and Figure 1—figure supplement
1A). Filaggrin (FLG) expression was similar to that of the controls (Figure 1—figure supplement
1A). We also observed a rich dermal infiltrate comprised of activated (b1 Tryptase+) mast cells, gran-
ulocytes, dendritic cells and, less abundant, T cells and macrophages (Figure 1C–D and Figure 1—
figure supplement 1B). In line with the dermal inflammatory reaction, D/Dep2 epidermis was charac-
terized by the robust expression of the keratinocyte activation marker K6, of the cell adhesion mole-
cule ICAM1, and by the sporadic expression of MHC class II molecules (Figure 1E), all upregulated
in inflammatory conditions including atopic dermatitis (Freedberg et al., 2001; Fan et al., 2003;
Caughman et al., 1992). Consistent with this, D/Dep2 epidermal lysates enriched in K5/K10-positive
keratinocytes (Doma et al., 2013) contained increased amounts of the cytokine TSLP, associated
with skin allergic disorders (Ziegler et al., 2013) (Figure 1F), as well as of other chemokines and
cytokines, with CCL7, IL18, IL5 and IL13 levels significantly higher than controls (Figure 1G).
Epidermal ablation of BRAF and RAF1 had profound systemic effects. The mice failed to thrive
(Figure 2A) and presented with enlarged spleens and lymph nodes. The splenomegaly could largely
be attributed to increased numbers of Mac1+Gr1+ cells (Figure 2B), a cell type found both in the
spleen of a mouse model of FITC contact hypersensitivity/S. aureus infection and in the blood and
skin infiltrates of atopic dermatitis patients (Skabytska et al., 2014). The lymph nodes contained ele-
vated numbers of activated T, B, and dendritic cells (Figure 2C). In the blood, we observed leukocy-
tosis and increased amounts of the chemokines CCL2 and CCL7, as well as of GCSF; in addition,
serum IgEs were elevated in D/Dep2 mice (Figure 2D). Thus, the phenotype of adult D/Dep2 mice
resembled a skin-specific allergic disease.
To determine whether the systemic phenotype was secondary to the severe skin inflammation
observed in adult animals, we examined D/Dep2 mice at weaning (3 weeks of age), at which stage
they did not groom more than control littermates nor showed any signs of skin rash, except a mild
eyelid irritation (Figure 3—figure supplement 1A). Skin architecture and keratinocyte proliferation
were not altered at this stage (Figure 3—figure supplement 1A). In terms of dermal infiltrate, a 2-
fold increase in mast cells could already be observed, but these cells were not activated (Figure 3A
and Figure 3—figure supplement 1A). Granulocytes and dendritic cell numbers were indistinguish-
able in 3 weeks old F/F2 and D/Dep2 littermates (Figure 3—figure supplement 1A). In the epider-
mis, ICAM1 expression was slightly upregulated, while K6 and MHC II expression could not be
detected (Figure 3A and Figure 3—figure supplement 1B). TSLP, CCL2, CCL7, and a number of
cytokines (GMCSF, IL6, 4, 5, 13, 2) were already significantly elevated in the epidermal lysates, while
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Figure 1. Compound deletion of BRAF and RAF1 in the epidermis leads to severe skin inflammation in adult mice.
(A) BRAF and RAF1 are efficiently deleted in epidermal cells as shown by PCR analysis of tail tissue and
immunoblotting of epidermal lysates isolated from 3 weeks old F/F2 and D/Dep2 (n = 4). ACTB is shown as a
loading control. (B) Macroscopic appearance of newborn and adult F/F2 and D/Dep2 mice. Arrowhead highlights
the open eye phenotype of D/Dep2 pups. (C) Hematoxylin/eosin (H and E) staining shows epidermal thickening
and dermal inflammatory infiltrates in D/Dep2 mice. BrdU incorporation confirms hyperproliferation in the basal
layer of D/Dep2 epidermis. The numbers in the inset represent BrdU+ cells/mm2 of epidermis (n = 5–7, mean ±
SEM). Infiltrating cells: activated mast cells (b1 Tryptase+), granulocytes (esterase+), dendritic cells (CD11c+). (D)
Quantification of the infiltrating cells: T cells (CD4+ and CD8+), macrophages (F4/80+), total mast cells (MC,
toluidine blue+), granulocytes (GR, esterase+). (E) Increased expression of K6, ICAM1, and MHC II in D/Dep2
keratinocytes/epidermis. Representative images (C, E) and quantification (D) of 5–7 individual couples. Scale bars,
50 mm. (F) Inflammatory chemokines and cytokines in epidermal lysates (n = 3–4). TSLP levels were determined by
Figure 1 continued on next page
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only a trend could be observed for others (Figure 3B and Figure 3—figure supplement 1C). Sys-
temically, enlarged lymph nodes contained increased amounts of activated T, B, and dendritic cells,
while the spleen was normal both in size and cell composition (Figure 3C and Figure 3—figure sup-
plement 1D). In the blood, the number of monocytes and granulocytes was increased, as were the
levels of CCL2, CCL7, and GCSF. However, no significant difference in serum IgEs could be
observed at this point (Figure 3D). The increase in T, B, and dendritic cells in lymph nodes and the
granulocytosis could be traced as far back as 10 days of age, at which time point GCSF was the only
cytokine elevated in the serum of D/Dep2 mice (Figure 3E–F). Thus, ablation of both Braf and Raf1
in mouse epidermis does not directly disturb skin architecture but rather affects the cross-talk
between keratinocytes and the innate and adaptive immune system.
Lack of epidermal BRAF and RAF1 causes transient inside-out barrier
defects
Inflammatory skin conditions often involve impaired skin barrier function. D/Dep2 embryos per-
formed normally in an outside-in dye penetration assay, indicating that stratum corneum permeabil-
ity was not affected (Figure 4A). We next monitored the weight of E18.5 embryos of different
Figure 1 continued
immunoblotting and quantified by Image J. ACTB served as a loading control. The results were normalized by
arbitrarily setting one of the F/F2 samples as 1 and plotted as mean ± SEM. Data represent mean ± SEM.
p = 0.011, p1 = 0.001, p2 = 0.007, p3 = 0.001, p4 = 3.06E-6, p5 = 1.37E-4, p6 = 0.002, p7 = 0.049, p8 = 0.042,
p9 = 0.046 and p10 = 0.001.
DOI: 10.7554/eLife.14012.003
The following figure supplement is available for figure 1:
Figure supplement 1. Local inflammation in adult mice lacking BRAF and RAF1 in the epidermis.
DOI: 10.7554/eLife.14012.004
Figure 2. Inflammatory response in adult D/Dep2 animals. (A) The body weight of D/Dep2 mice is significantly reduced compared to their littermates
(n = 5). The data was analyzed by two-way analysis of variance (ANOVA) test. (B) Increased spleen/body weight ratio and increased numbers of splenic
Mac1+Gr1+ cells in adult D/Dep2 animals (n = 4–5). (C) Enlarged lymph nodes and and activated T, B, and dendritic cells in adult D/Dep2 (n = 4–8). T
cells (CD4+ or CD8+) and B cells (B220+) activation was determined by costaining with CD69; activated dendritic cells were identified as CD11c+ and
MHC IIhi or CD80+. (D) Circulating blood cells and plasma levels of chemokines and IgE antibodies in adult mice (n = 6–8). Data represent mean ± SEM.
p1 = 0.0002, p2 = 0.023, p3 = 0.002, p4 = 0.002, p5 = 9.83E-8, p6 = 6.31E-7, p7 = 2.91E-7, p8 = 0.004, p9 = 0.001, p10 = 0.008, p11 = 0.011,
p12 = 0.046, p13 = 0.050, p14 = 3.65E-4 and p15 = 0.001.
DOI: 10.7554/eLife.14012.005
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Figure 3. Local and systemic inflammatory phenotype in young D/Dep2 animals. (A) Local inflammation in 3 weeks
old D/Dep2 animals. Total mast cells (toluidine blue staining, TB; quantified in the plot, n = 4–5) and ICAM1
staining. Scale bars, 25 mm. (B) Inflammatory chemokines and cytokines in epidermal lysates (n = 4–5). TSLP levels
were determined by immunoblotting and quantified and analyzed as in Figure 1F. TUBA served as a loading
control. (C, D) Systemic inflammatory parameters in 3 weeks old mice. (C) Lymph node size and composition
(n = 4). (D) Circulating blood cells (n = 8) and plasma concentration of IgE (n = 8) and chemokines (n = 9). (E, F)
Systemic inflammatory parameters in 10 days old mice. (E) Lymph node size and composition (n = 4–10). (F)
Hemogram showing elevated amounts of granulocytes (upper panel, n = 4–7) and plasma chemokine levels
showing increased GCSF (n = 4). Data represent mean ± SEM. p1 = 0.016, p2 = 0.041, p3 = 0.013, p4 = 0.040,
p5 = 0.013, p6 = 0.032, p7 = 0.026, p8 = 0.007, p9 = 0.029, p10 = 0.048, p11 = 0.015, p12 = 0.018, p13 = 0.033,
Figure 3 continued on next page
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genotypes for 9 hr after birth as a proxy for transepidermal water loss and thus for the barrier func-
tion of tight junctions. D/Dep2 embryos lost three-fold the weight of littermate controls (Figure 4B).
Molecularly, reduced expression of E-cadherin (CDH1), an adherens junction protein known to regu-
late tight junctions (Tunggal et al., 2005), and of the tight junction protein claudin 1 (CLDN1), which
is crucial for the maintenance of the inside-outside barrier (Furuse et al., 2002) and has been found
downregulated in atopic dermatitis patients (De Benedetto et al., 2011) was still evident at P3 in D/
Dep2 epidermis, while occludin expression was normal (OCLN) (Figure 4C). The architecture of P3
D/Dep2 skin was indistinguishable from that of controls (Figure 4—figure supplement 1A); P3 epi-
dermal lysates contained highly variable amounts of chemokines and cytokines, predominantly
CCL2, IL6 and IL18. All were increased in the D/Dep2 epidermal lysates, albeit not significantly (Fig-
ure 4—figure supplement 1B). The E-cadherin and claudin 1 downregulation was transient and was
no longer detectable in 3 weeks old D/Dep2 mice (Figure 4D). Single deletion of RAF1 (RAF1D/Dep)
and BRAF (BRAFD/Dep) did not lead to increased body weight loss in E18.5 embryos; consistently,
Figure 3 continued
p14 = 0.036, p15 = 3.00E-04, p16 = 3.88E-05, p17 = 0.026, p18 = 0.021, p19 = 0.048, p20 = 0.034, p21 = 0.042,
p22 = 0.008, p23 = 0.001, p24 = 0.018, p25 = 0.005, p26 = 0.001, p27 = 0.001, p28 = 0.011 and p29 = 0.014.
DOI: 10.7554/eLife.14012.006
The following figure supplement is available for figure 3:
Figure supplement 1. Local and systemic response in 3 weeks old 4/4ep2 animals.
DOI: 10.7554/eLife.14012.007
Figure 4. Transient inside-outside barrier defects in D/Dep2 animals. (A) Intact outside-in barrier function (determined by toluidine blue penetration of
the stratum corneum) in E19.5-day-old D/Dep2 embryos compared to controls (n = 6). Representative pictures; two independent experiments were
performed with identical results. (B) Increased water loss in the D/Dep2 E18.5 embryos as demonstrated by weight analysis. Results are displayed as
percentage of initial weight (n = 41 for F/F2 and n = 11 for D/Dep2). The data was analyzed by two-way analysis of variance (ANOVA) test. (C, D)
Immunoblot analysis of CDH1, CLDN1 and OCLN expression in epidermal lysates of 3 days old (C, n = 3; quantification shown in the plot, performed
as in Figure 1F) or 3 weeks old D/Dep2 animals. TUBA and GAPDH are shown as loading controls. Data represent mean ± SEM. p1 = 0.0001,
p2 = 0.028, p3 = 0.020.
DOI: 10.7554/eLife.14012.008
The following figure supplement is available for figure 4:
Figure supplement 1. Skin architecture and inflammatory factors in 3 days old F/F2 and 4/4ep2 animals.
DOI: 10.7554/eLife.14012.009
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the expression levels of tight junction proteins were normal in P3 epidermis (Figure 4—figure sup-
plement 1C–D).
To assess the relevance of the transient perinatal barrier defect of D/Dep2 mice, we deleted Braf
and Raf1 in 3 weeks old mice using tamoxifen-inducible Krt5-Cre (Indra et al., 1999). These animals,
termed D/Dep2TX, showed conversion of both F to D alleles and strongly reduced expression of
BRAF and RAF1 proteins in tail tissue (Figure 5A). D/Dep2TX mice developed a milder disease than
the D/Dep2 mice, characterized by much slower kinetics (8 months between ablation and overt
symptoms), moderate keratinocyte hyperproliferation (assessed as increased epidermal thickness)
and activation (as determined by K6 and ICAM1 expression), as well as by a modest increase in acti-
vated mast cells and granulocytes in the dermis (Figure 5B). At the systemic level, we observed mild
splenomegaly with an increase in Mac1+Gr1+ cells (Figure 5C) as well as enlarged lymph nodes con-
taining activated lymphocytes and dendritic cells (Figure 5D and Figure 5—figure supplement 1).
Increased numbers of lymphocytes and granulocytes were found in the blood, while IgE levels were
comparable to controls (Figure 5E). Thus, circumventing the transient barrier defect of the D/Dep2
animals postponed and attenuated the clinical manifestation of the disease.
Increased JNK and reduced ERK activation in D/Dep2 epidermis and
cells
To gain insight in the molecular correlates of the phenotype, we analyzed MAPK signaling in the epi-
dermis. We observed decreased activation of ERK and increased activation of JNK, assessed by the
phosphorylation of both MAPK and their respective downstream targets pRSK and pJUN, in non-
lesional epidermis of adult D/Dep2 and D/Dep2TX mice; in contrast, phosphorylation of the p38 tar-
get MAPKAPK2 was not affected (Figure 6A and B). A more detailed analysis of 3 weeks old animals
confirmed low ERK activation and increased phosphorylation of JNK (and, to a lower degree, p38) in
D/Dep2 epidermal lysates (Figure 6C). Consistent with this phosphorylation pattern, the levels of the
dual specificity phosphatase DUSP1 and DUSP10, negative regulators of the stress kinases
(Patterson et al., 2009), were low in the D/Dep2 lysates. BRAFDep lysates were characterized by
reduced ERK phosphorylation only, while RAF1Dep lysates showed increased phosphorylation of all
three MAPK. The expression of ICAM1 as marker of inflammation was detected only in the D/Dep2
lysates, leading to the hypothesis that the combination of high JNK, low ERK activation is at the
basis of the inflammatory phenotype of D/Dep2 animals (Figure 6C).
Inhibition of ERK activation induces inflammatory skin disease in
RAF1Dep mice
We tested this hypothesis by treating 6 weeks old RAF1Dep animals with a MEK inhibitor (MEKi; tra-
metinib, in clinical use; daily by gavage for 32 days) to decrease ERK activation and determine
whether this would phenocopy the D/Dep2 disease. MEKi efficiently reduced ERK phosphorylation
and slightly increased JNK phosphorylation in both control and RAF1Dep epidermal lysates, but
increased p38 phosphorylation was only observed in the RAF1Dep (Figure 7A). Consistently, MEKi
reduced the expression of the phosphatases DUSP1 and 10 and of CLDN1 in RAF1Dep epidermis
only (Figure 7A). Within a month, the RAF1Dep animals developed an inflammatory skin disease
characterized by K6 and ICAM1 expression in the epidermis, by the presence of activated dermal
mast cells and by an increase in TSLP (Figure 7B). In control animals, inhibitor treatment did not
affect, or reduced chemo- or cytokine amounts; GMCSF, IL5, IL2 and CCL4 were reduced signifi-
cantly, and a trend could be observed for IL4, IL17, IL27, and CXCL1. In contrast, a comparison
between inhibitor-treated RAF1F/F and RAF1Dep lysates revealed a significant upregulation of
CCL2, GMCSF, IL18, IL5, IL13, IL2, IL17 and CCL4 (Figure 7C and Figure 7—figure supplement 1).
This correlated with increased Mac1+Gr1+ cells in the spleen and activated T, B, and dendritic cells
in the lymph nodes (Figure 7D) as well as with increased circulating IgEs and granulocytosis
(Figure 7E). Thus, inhibiting ERK in the RAF1Dep animals recreates the immunological environment
necessary to bring about a disease very similar to that observed in D/Dep2 mice.
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Figure 5. Local and systemic inflammation in D/Dep2TX mice. (A) PCR analysis of tail tissue (left) and immunoblot
analysis of epidermal lysates obtained from D/Dep2TX animals. (B) Macroscopic appearance of D/Dep2TX mice and
histological analysis of H&E sections. Scale bars, 25 mm. Infiltrating cells: mast cells (MC; TB+), activated mast cells
(b1 Tryptase+; modest), granulocytes (GR; esterase+). The plot shows a quantification of the histological analysis.
(C) Mild splenomegaly with increased numbers of Mac1+Gr1+ cells in D/Dep2TX animals. (D) Activated T cells, B
cells and dendritic cells in the lymph nodes of D/Dep2TX animals. (E) Mild lymphocytosis and significantly elevated
granulocyte numbers in D/Dep2TX mice. The right panel shows comparable IgE plasma levels in control and D/D
ep2TX animals. Data are plotted as mean ± SEM (n = 5; p1 = 0.034, p2 = 0.014, p3 = 0.005, p4 = 2.63E-4,
p5 = 0.001, p6 = 0.001, p7 = 0.019 and p8 = 0.042).
DOI: 10.7554/eLife.14012.010
Figure 5 continued on next page
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The inflammatory skin disease of D/Dep2 mice can be prevented by
JNK inhibition but not by MyD88, TNF or caspase 1/11 ablation
Collectively, the data above suggest that JNK activation was responsible for the inflammatory skin
phenotype. To assess whether this was the case in vivo, we treated D/Dep2 animals with the specific
peptide inhibitor D-JNKI1. D-JNKI1 efficiently blocked JUN phosphorylation, increased ERK and RSK
phosphorylation (Figure 8A), and prevented the development of the disease as determined by
ICAM1 and TSLP expression in the epidermis as well as by eyelid inflammation and mast cells accu-
mulation in the dermis (Figure 8A–B). Consistent with the data in Figure 3—figure supplement 1B,
K6 expression could not be observed in the interfollicular epidermis in any of the experimental
groups (Figure 8—figure supplement 1A). Compared to untreated 3 weeks old animals, vehicle
(TAT-peptide) alone had minor effects on the level of some chemokines and cytokines; the increase
in IL17 and IL18 in TAT-peptide-treated D/Dep2 vs F/F2 animals became significant; the opposite
was observed for CCL7, IL13 and IL4 (compare Figures 3B and 8C; and Figure 3—figure supple-
ment 1 with Figure 8—figure supplement 1B ). Treatment with D-JNKI1 reduced chemo- and cyto-
kines in epidermal lysates of D/Dep2 animals to levels indistinguishable from, or lower than (CCL2,
CCL4, GMCSF and IL4), those of F/F2 controls. Exceptions were IL6, which was significantly reduced
in D/Dep2, but not in F/F2 epidermal lysates; and IL5, which was not affected by the inhibitor in
either genotype (Figure 8C and Figure 8—figure supplement 1B). At the systemic level, D-JNKI1
normalized the numbers of activated B and dendritic cells in lymph nodes, while the numbers of acti-
vated T cells where reduced in both F/F2 and D/Dep2 lymph nodes (Figure 8D). Thus, JNK activation
and the resulting chemo- and cytokine accumulation in the epidermis are required for disease
development.
To determine whether the increased JNK activation observed in the D/Dep2 animals was due to a
specific signal, we mated them to MyD88 knockout animals (Adachi et al., 1998), to block both TLR
(with the exception of TLR3) and IL1 signaling (Janssens and Beyaert, 2002). We also used TNFA
knockout mice to prevent TNF signaling (Kuprash et al., 2005), and caspase 1/11 knockout mice to
ablate IL1 and IL18 production (Smith et al., 1997). None of these knockouts altered the progres-
sion (onset around 2 months of age) or severity of the D/Dep2 skin disease (Figure 8—figure supple-
ment 2). The Myd88 knockout, however, reduced the splenomegaly observed in the D/Dep2 mice.
This specific phenotype is caused by an increase in Mac1+/Gr1+ splenocytes (Figure 2B), and its
selective rescue in the compound D/Dep2;MyD88 knockout animals is likely due to the crucial role of
MyD88 in the generation of these cells (Arora et al., 2010; Delano et al., 2007).
Interfering with the JNK pathway decreases the production of
proinflammatory molecules in primary D/Dep2 keratinocytes and RAF
knockdown HaCat cells
A concomitant increase in JNK activation and decrease in ERK activation is the basis of the skin dis-
ease of D/Dep2 animals. To test whether this molecular phenotype was cell-autonomous and to gain
some insight in the molecular mechanisms underlying JNK activation, we established and analyzed
primary keratinocytes cultures. D/Dep2 keratinocytes were “primed” for inflammation: they constitu-
tively expressed ICAM1 (Figure 9A) and, upon stimulation, significantly increased amounts of che-
mokines (CCL2, CCL7) and cytokines (IL6, IL18, TSLP, IL13, Figure 9B; IL4 was not detected under
these conditions). In addition, D/Dep2 keratinocytes showed decreased ERK activation in response
to EGF and a strong increase in pJNK when co-treated with proinflammatory stimuli (Figure 9A).
Treatment with D-JNKI1, a cell-penetrating, protease-resistant peptide that prevents JNK interaction
with its JBD-dependent targets (Borsello and Forloni, 2007), reduced the expression of the inflam-
matory proteins ICAM1, TSLP, CCL2 and CCL7, but did not have any major effect on ERK activation
Figure 5 continued
The following figure supplement is available for figure 5:
Figure supplement 1. Representative FACS analysis of lymph node and spleen cells isolated from adult F/F2TX D/
Dep2TX animals.
DOI: 10.7554/eLife.14012.011
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Figure 6. Molecular consequences of BRAF/RAF1 deletion in primary keratinocytes and epidermis. (A, B)
Immunohistochemical analysis of pERK and pJNK, their downstream targets pRSK and pJUN, and the p38
downstream target pMAPKAPK2 in adult F/F2 and D/Dep2 (A), and F/F2TX D/Dep2TX epidermis (B). Scale bars, 50
mm. The plots on the right show the percentage of positive cells in the epidermis (n = 4–5). (C) Immunoblot
analysis of MAPK signaling in 3 weeks old epidermal lysates (n = 4), quantified as in Figure 1F. ACTB is shown as
a loading control. Phosphorylation is expressed as the ratio between the signals obtained obtained with the
phosphospecific antibody and with the protein-specific antibody. In both cases, the data are normalized to one of
the F/F2 samples, which was arbitrarily set as 1. Data are plotted as mean ± SEM. p1 = 2.73E-4, p2 = 4.15E-5,
p3 = 0.042, p4 = 0.031, p5 = 0.001, p6 = 0.023, p7 = 0.038, p8 = 0.049, p9 = 0.010, p10 = 0.030, p11 = 0.033,
p12 = 0.023 and p13 = 0.018.
DOI: 10.7554/eLife.14012.012
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Figure 7. MEK/ERK inhibition in RAF1Dep animals phenocopies the D/Dep2 phenotype. RAF1Dep animals were
treated with a MEK inhibitor (MEKi; trametinib, daily by gavage for 32 days). (A) Immunoblot of epidermal lysates
showing the effect of MEKi on the phosphorylation and expression of the indicated proteins. GAPDH is shown as
a loading control. (B) Macroscopic appearance (top panels) and histological analysis of vehicle versus MEKi-treated
animals. Mast cells (TB+) and activated mast cells (b1 Tryptase+) are quantified in the plots on the left. Scale bars
25 mm. (C) Inflammatory chemokines and cytokines in epidermal lysates of MEKi treated-mice. TSLP levels were
determined by immunoblotting and quantified and analyzed as in Figure 1F. ACTB served as a loading control.
(D) Increased numbers of splenic Mac1+ Gr1+ cells and of activated T cells, B cells and dendritic cells in the lymph
nodes of MEKi-treated RAF1Dep animals. (E) Mild monocytosis and granulocytosis in MEKi-treated RAF1Dep
animals and elevated amount of plasma IgE. Data represent mean ± SEM (n = 3; p1 = 0.002, p2 = 0.017,
p3 = 0.003, p4 = 0.025, p5 = 0.041, p6 = 0.022, p7 = 0.023, p8 = 0.029, p9 = 0.010, p10 = 0.032, p11 = 0.044,
p12 = 0.053, p13 = 0.015, p14 = 0.001, p15 = 0.031, p16 = 0.049, p17 = 0.026, p18 = 0.038, p19 = 0.015,
Figure 7 continued on next page
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and on the stress kinase phosphatases DUSP1 and DUSP10, expressed at lower levels in D/Dep2 ker-
atinocytes (Figure 9C–D).
To ensure that the effects observed in the D/Dep2 cells and tissue could be reproduced by acute
ablation, we performed knockdown experiments in the human keratinocyte cell line HaCat. Concom-
itant silencing of BRAF and RAF1 (double knockdown, KD2) abolished basal ERK phosphorylation,
decreased ERK activation and increased JNK activation by a combination of EGF and proinflamma-
tory stimuli (Figure 9—figure supplement 1A). Constitutive ICAM1 expression was not observed in
KD2 cells, but they expressed higher levels of this molecule when treated with TNFa. ICAM1 expres-
sion was reduced by D-JNKI1 in KD2 cells and increased by MEKi in RAF1KD cells (Figure 9—figure
supplement 1B–C). CCL2 mRNA accumulation, which depends on concomitant stress kinase activa-
tion and ERK inhibition, was also elevated in a JNK-dependent manner in KD2 cells (Figure 9—fig-
ure supplement 1B); MEK inhibition strongly increased CCL2 mRNA in WT cells (Pastore et al.,
2005) and even more so in RAF1KD cells (Figure 9—figure supplement 1C).
Mixed lineage kinase 3 (MLK3) activates the JNK pathway (Gallo and Johnson, 2002) and can
function both as a positive regulator of ERK signaling, via kinase-independent mechanisms
(Chadee and Kyriakis, 2004; Chadee et al., 2006) and as a negative regulator of ERK, via JNK-
dependent mechanisms (Shen et al., 2003). Importantly, MLK3 binds to JIP1 (Whitmarsh et al.,
1998), and signal flow from this upstream kinase would be interrupted by D-JKNI1. We thus deter-
mined whether MLK3 was implicated in the imbalance in ERK/JNK signaling observed in D/Dep2 pri-
mary keratinocytes and in KD2 HaCat cells. MLK3 downregulation by two independent shRNAs
strongly reduced both ERK and JNK phosphorylation in F/F2 cells treated with EGF and proinflam-
matory stimuli; however, in D/Dep2 cells, only JNK phosphorylation was reduced (Figure 9E). Consis-
tently, MLK3 downregulation reduced ICAM1 upregulation and the induction of Ccl2 and Tslp
mRNA (Figure 9F). Essentially the same results were obtained by downregulating MLK3 in WT and
KD2 HaCat cells (Figure 9—figure supplement 1D). Thus, MLK3 is responsible for JNK activation
and the induction of inflammatory molecules in D/Dep2 keratinocytes and HaCat cells.
Discussion
BRAF and RAF1 prevent keratinocyte-driven allergic inflammation
Keratinocytes have long been known to contribute to the pathogenesis of skin inflammatory disor-
ders, but whether they do so by reacting to stimuli produced by immune cells or by initiating the
cascade leading to the disease is still a matter of debate. We describe an essential role of BRAF and
RAF1 in keratinocytes in the control of allergic inflammation. Mice lacking BRAF/RAF1 in keratino-
cytes develop a disease clinically very similar to human atopic dermatitis (Bieber, 2010). It starts
with a barrier defect accompanied by the reduced expression of crucial tight junction proteins and
by a marginally increased expression of chemokines and cytokines, particularly CCL2, IL6 and IL18. It
then progresses to a stage in which the skin appears unaffected, yet both local (mast cell infiltration,
chemokine and cytokine production) and systemic (T and B cell activation, increased amounts of cir-
culating leukocytes and chemokines) anomalies become evident while TSLP and IgE levels are only
slightly increased. This is reminiscent of the early phase of atopic dermatitis in children, prior to IgE
sensitization (Bieber, 2010). Unlike the majority of atopic dermatitis patients (De Benedetto et al.,
2012), however, the D/Dep2 animals don’t have a stratum corneum defect, which may help explain
the lack of symptoms at this stage. Adult mice present with a full-fledged disease characterized by
rich dermal infiltrates, increased cytokine production, clearly elevated IgEs and mast cell activation,
in good correlation with the intense pruritus causing extensive scratching and self-inflicted wounds.
Figure 7 continued
p20 = 0.001, p21 = 0.005, p22 = 0.002, p23 = 0.033, p24 = 0.006, p25 = 0.039, p26 = 0.025, p27 = 0.004,
p28 = 0.020, p29 = 0.027 and p30 = 0.028).
DOI: 10.7554/eLife.14012.013
The following figure supplement is available for figure 7:
Figure supplement 1. Epidermal chemokine and cytokine levels in MEKi treated mice.
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Figure 8. D-JNKI1 treatment rescues inflammation in D/Dep2 mice. Mice were treated with D-JNKI1 or TAT peptide (22 mg/kg i.p. at 10 days of age)
and analyzed after 12 days (A) D-JNKI1 treatment prevents disease onset in D/Dep2 mice. Immunoblot of epidermal lysates showing the effect of
D-JNKI1 on the phosphorylation and expression of the indicated proteins, quantified as in Figure 1F. ACTB is shown as a loading control. (B–D)
Decreased eyelid inflammation, mast cells infiltration (B; TB+; quantified in the plot on the right), epidermal chemokine/cytokine levels (C) and activated
T cells, B cells and dendritic cells in lymph nodes (D) in D-JNKI1-treated D/Dep2 mice. Scale bars, 25 mm. Data represent mean ± SEM (n = 3–5;
p1 = 0.026, p2 = 0.042, p3 = 0.022, p4 = 0.048, p5 = 0.044, p6 = 0.020, p7 = 0.025, p8 = 0.018, p9 = 0.016, p10 = 0.014, p11 = 0.023, p12 = 0.011,
p13 = 0.039, p14 = 0.049, p15 = 0.015, p16 = 0.003, p17 = 1.70E-4, p18 = 0.008, p19 = 0.008, p20 = 0.004, p21 = 0.003, p22 = 0.017, p23 = 0.026,
p24 = 0.027, p25 = 0.005, p26 = 2.13E-6, p27 = 4.50E-8, p28 = 1.39E-5, p29 = 0.001, p30 = 0.001, p31 = 0.001, p32 = 0.023, p33 = 2.35E-4, p34 = 0.050,
p35 = 0.002, p36 = 0.050 and p37 = 0.012).
DOI: 10.7554/eLife.14012.015
The following figure supplements are available for figure 8:
Figure supplement 1. K6 expression and epidermal chemokine and cytokine levels in D-JNKI1-treated mice.
DOI: 10.7554/eLife.14012.016
Figure supplement 2. The inflammatory phenotype of D/Dep2 mice is not rescued by MyD88, caspase 1/11, or TNF knockout.
DOI: 10.7554/eLife.14012.017
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Figure 9. Increased stress kinase signaling and JNK pathway-dependent cytokine and chemokine production by primary keratinocytes lacking BRAF
and RAF1. (A) Reduced ERK phosphorylation and increased JNK/p38 activation in primary D/Dep2 keratinocytes stimulated with EGF and/or TNFa and
IL1b for 15 min. (B) Increased cytokine and chemokine production in primary D/Dep2 keratinocytes treated with EGF, TNFa and IL1b for 24 hr. Cytokine
and chemokine production was determined by multiplex analysis, except for TSLP which was quantified by ELISA. Data represent mean ± SEM of 3–5
biological replicates. (C–D) Cells were pretreated with D-JNKI1 inhibitors prior to stimulation with EGF, TNFa and IL1b for 15 min (C) or 24 hr (D). Data
represent the mean ± SEM of technical replicates (n = 3). (E–F) Effect of shRNA-mediated Mlk3 silencing on ERK and JNK phosphorylation and ICAM1
expression (E; stimulation with EGF, TNFa and IL1b for 15 min) and on the expression of Ccl2 and Tslp mRNA (F; stimulation with EGF, TNFa and IL1b
for 24 hr) by F/F2 and D/Dep2 keratinocytes. shRen, shRNA targeting Renilla, used as a control; sh1 and sh2, targeting Mlk3, binding sites nucleotide
2266–2285 and 2383–2402, respectively. The shRNAs were encoded by lentiviral vectors coexpressing GFP. GFP immunoblots are shown to confirm
similar levels of infection in all samples. Data represent mean ± SEM of 4 biological replicates. Each keratinocyte culture represents a pool of three
mice. Immunoblots are representative of three independent experiments. p1 = 0.041, p2 = 0.040, p3 = 1.89E-4, p4 = 0.018, p5 = 0.046, p6 = 0.020,
p7 = 0.008, p8 = 0.016, p9 = 0.001, p10 = 0.018, p11 = 3.23E-4, p12 = 1.47E-4, p13 = 0.007, p14 = 0.03, p15 = 0.035, p16 = 0.023 and p17 = 0.046.
DOI: 10.7554/eLife.14012.018
Figure 9 continued on next page
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The initial barrier defect contributes to full-fledged disease, since ablation of BRAF/RAF1 after the
third week causes a less severe condition lacking IgE sensitization and mast cell activation, yet reca-
pitulating the systemic symptoms of the disease. This could be likened to late-onset, IgE-sensitiza-
tion-independent dermatitis (Bieber, 2010). Thus, BRAF and RAF1 act together to ensure the timely
establishment of the inside-out barrier of the epidermis and to prevent allergic inflammation. The
data support the hypothesis that the keratinocytes play a primary role in the pathogenesis of atopic
dermatitis, and the D/Dep2 animals may be useful as a model for this disease (Figure 10).
Figure 9 continued
The following figure supplement is available for figure 9:
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Figure 10. Molecular and physiological defects in mice lacking BRAF and RAF1 in the epidermis. Compound BRAF/RAF1 ablation in keratinocytes
induces an imbalance in MAPK signaling, resulting in low ERK, high JNK activation. This causes early inside-outside barrier defects accompanied by
reduced CDN1 expression (yellow arrows), followed by a breakdown of the immunological barrier and local as well as systemic allergic inflammation
akin to atopic dermatitis, characterized by the presence of Th2 cytokines in the epidermis. The phenotype can be prevented by inhibiting the JNK
pathway in D/Dep2 animals and cells, and phenocopied by inhibiting the ERK pathway in Raf1D/Dep animals. Systemic effects (lymph node involvement,
circulating IgEs) are separated from local effect by a dashed line. B (B cells), T (T cells), Mc (Mast cells), D (dendritic cells).
DOI: 10.7554/eLife.14012.020
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A set of chemokines and Th2 cytokines underlies D/Dep2 allergic
inflammation
In this respect, our experiments provide information about the minimal set of keratinocyte-derived
factors required for the establishment of allergic, atopic dermatitis-like inflammation.
In the phase before IgE sensitization and mast cell activation, we detected significantly higher lev-
els of TSLP, CCL2, CCL7, GMCSF, IL2, IL5, IL6, and IL13 in D/Dep2 epidermal lysates; most chemo-
kines and cytokines in the D/Dep2 animals were sensitive to D-JNKI1 inhibitor treatment, which
brought D/Dep2 and F/F2 epidermal lysates down to indistinguishable levels. Conversely, the set of
cytokines (TSLP, IL5, IL13, IL18, borderline IL2 and IL17) observed in adult, diseased D/Dep2 mice
was similar to that promoting symptomatic disease in RAF1Dep animals treated with trametinib,
which showed an increase in TSLP, IL2, IL5, IL13, as well as in IL18. These data can be interpreted to
mean that ERK signaling negatively regulates the production of allergy-promoting factors. However,
it is important to note that trametinib treatment reduced IL2 and IL5 as well as GMCSF in the F/F2
epidermis, indicating that sensitivity to ERK inhibition must be seen in the context of altered cell-
autonomous signaling (increased JNK activation in RAF1Dep epidermis) and/or tissue milieu. Along
the same lines, D/Dep2 keratinocytes treated with inflammatory stimuli were significantly more effi-
cient than F/F2 in producing CCL2, CCL7, IL6, IL18, TSLP and IL13, but not IL2 or IL5, resembling,
but not fully reproducing, the spectrum observed in epidermal lysates. At this stage, it is impossible
to determine whether these discrepancies might be due to the presence of cell types other than ker-
atinocytes in the epidermal lysates or whether the culture and stimulation conditions used did not
recapitulate the situation in vivo.
Be that as it may, the range of chemokines and cytokines overrepresented in the D/Dep2 mice
and in the trametinib-treated RAF1Dep mice is consistent with allergic inflammation. In this respect,
strong expression of CCL2 has been reported in the basal keratinocytes of atopic dermatitis patients
(Giustizieri et al., 2001), and expression of CCL7, which can attract basophils, eosinophils, mast
cells and Th2 cells, can be induced by allergens in atopic skin (Ying et al., 1995).
TSLP, the signature cytokine of allergic disease, promotes the functions of these same cell types
(Ziegler et al., 2013), and is responsible for the extreme itching accompanying atopic dermatitis
(Wilson et al., 2013). High levels of TSLP (Liu, 2006), but also of IL5 and IL13 have been reported in
the skin of atopic dermatitis patients, particularly in those with elevated IgEs (Jeong et al., 2003). In
mice, it could be shown that the expression of TSLP (Liu, 2006), IL4, IL5 and IL13 induces atopic der-
matitis as well as asthma (Lee and Flavell, 2004), and IL5 knockout mice exposed to allergens are
less prone than wild-type to develop skin eosinophilia and epidermal thickening (Spergel et al.,
1999). Finally, expression of IL13 in keratinocytes is sufficient to induce a disease mimicking atopic
dermatitis (Zheng et al., 2009). Thus, these cytokines appear instrumental for the development of
atopic dermatitis with IgE sensitization. IL18, on the other hand, can stimulate both Th1 and Th2
responses (Nakanishi et al., 2001), and appears to be causally involved in a different type of atopic
dermatitis. IL18 is essential for the induction of dermatitis by the epidermis-restricted expression of
caspase 1, the enzyme that generates active IL18 from its precursor. In addition, expression of IL18
in keratinocytes induces a late-onset dermatitis associated with mastocytosis, but independent of
IgE production (Konishi et al., 2002). More recently, IL18 knockout mice were shown to be resistant
to infection-associated atopic dermatitis, in a mouse model generated by perturbing the stratum
corneum with detergent prior to topical application of S. aureus protein A (Terada et al., 2006).
However, stratum corneum defects could not be observed in D/Dep2 mice, and caspase 1 ablation
does not modify the course of the D/Dep2 disease. Thus, IL18 is not a determining factor in the con-
text of the D/Dep2 dermatitis, which rather resembles a Th2/IgE-driven disease.
An imbalance in MAPK signaling underlies skin inflammation in D/Dep2
mice
Ablation of BRAF and RAF1 in the epidermis has non-redundant functions converging on MAPK cas-
cades. Decreased ERK and increased JNK activation are observed in D/Dep2 epidermis in vivo inde-
pendently of the severity of the disease as well as in D/Dep2 keratinocytes and BRAF/RAF1
knockdown HaCat cells. Thus, the imbalance in MAPK signaling represents an intrinsic defect of cells
and tissues lacking BRAF/RAF1. While BRAF ablation, as in many other tissues/organs, is responsible
for reduced ERK activation (Desideri et al., 2015), RAF1 ablation correlates with a previously
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unnoticed increase in stress kinase activation. Consistent with this, we have observed a reduction in
the expression of two DUSPs involved in the inactivation of stress kinases, which is strongest in the
D/Dep2 epidermis. This is in line with the reported positive role of p38 in the induction of DUSP
expression and of ERK in its attenuation at multiple levels (Caunt and Keyse, 2013; Taxman et al.,
2011), which would predict that decreased ERK signaling would be needed to reduce DUSP expres-
sion and stabilize JNK phosphorylation when p38 is active. Importantly, both DUSPs have been
implicated in the production of cytokines by immunocompetent cells and in murine models of inflam-
matory and autoimmune disease (Lang et al., 2006).
We could further identify MLK3 as the kinase responsible for JNK activation as well as for the
expression of inflammatory molecules in primary D/Dep2 keratinocytes and BRAF/RAF1 knockdown
HaCat cells costimulated with EGF, TNFa and IL1b (as a proxy for the alterations observed in the D/
Dep2 animals). The lack of basal JNK activation in unstimulated cells suggests a cross-talk at the level
of BRAF/RAF1 and MLK3 rather than direct MLK3 activation by BRAF/RAF1 ablation. Such a cross-
talk was previously reported to occur in the context of ERK signaling, which is positively regulated
by MLK3 via the stabilization of the RAF dimer (Chadee and Kyriakis, 2004; Chadee et al., 2006). It
is possible that in turn, BRAF and RAF1 would restrict the involvement of MLK3 in the JNK pathway,
at the same time promoting ERK and reducing JNK activation in stimulated cells (Figure 10).
While the mechanistic details remain to be fully elucidated, the relevance of the imbalance in
MAPK signaling for the development of the atopic dermatitis-like disease in D/Dep2 animals was
shown in vivo in two complementary ways: 1) by preventing disease onset with the specific peptide
inhibitor D-JNKI1; and 2) by inducing disease in healthy RAF1Dep animals with a MEK inhibitor (Fig-
ure 10). The second set of experiments also clearly shows that the function of BRAF and RAF1 in the
epidermis is not redundant. Finally, the combined RAF knockout and inhibitor data help explain why
in patients the cutaneous toxicity of RAF inhibitors, which increase ERK activation, is mostly related
to hyperproliferation (Anforth et al., 2013), while inhibitors of ERK activation promote the onset or
exacerbate the course of cutaneous inflammatory reactions involving stress kinase activation
(Curry et al., 2014).
Materials and methods
Animal studies and inhibitor treatment
All strains were maintained on a Sv/129 background. Krt5-CreBraf f/f;Raf1f/f mice were generated for
this study by mating Krt5-Cre;Braff/f:: Krt5-Cre;Raf1f/f animals. These strains, the Krt5-CreER(TX);Braf
f/f;Raf1f/f mice as well as their genotyping and the tamoxifen-induced deletion of the RAF alleles
have been previously described (Kern et al., 2013; Ehrenreiter et al., 2005). Inducible RAF deletion
was performed at the age of three weeks.
Krt5-CreBraf f/f;Raf1f/f were mated with MyD88 (Adachi et al., 1998), TNF (Kuprash et al., 2005),
and caspase 1/11 (Smith et al., 1997) knockout mice, all maintained on a C57BL/6 background, to
test the contribution of the respective signaling pathways to the Krt5-CreBraf f/f;Raf1f/f phenotype.
In selected experiments, the MEK inhibitor GSK1120212 (trametinib, Selleckchem, Germany) was
applied daily by gavage for 32 days (Doma et al., 2013). The peptide inhibitor D-JNKI1 was synthe-
sized at the Istituto di Ricerche Farmacologiche ’Mario Negri’ (Milano, Italy), as previously described
(Borsello et al., 2003). Ten days old animals were injected once i.p. (22 mg/kg) with D-JNKI1 or
TAT peptide control ((D-Pro1,2) retro-(D-HIV-TAT (aa 48-57), Enzo Life Sciences, NY, USA, BML-
El384-0001). Animal experiments were authorized by the Austrian Ministry of Science, Research and
Economy.
Histology and immunohistochemistry
H&E staining, TUNEL, BrdU incorporation and immunohistochemistry were carried out as described
(Ehrenreiter et al., 2009) on paraffin or cryostat sections. The following antibodies were used:
b1 Tryptase (AF1937) and ICAM1 (AF796) from R&D Systems (Minneapolis, MN); CD11c (14–0114)
and MHC II (14–5321) from Affymetrix eBioscience (Santa Clara, CA); K6 (905701), K5 (905501), K10
(905401) and Involucrin (924401) from BioLegend (San Diego, CA); F4/80 (AbDSerotec, UK,
MCAP497); CD4 (550280) and CD8 (550281) from BD Biosciences (San Jose, CA); Filaggrin
(ab24584), pRSK (ab32413) and pJNK (ab4821) from Abcam (UK); pJUN (9164) and pERK (4376)
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from Cell Signaling Technology (Danvers, MA). Granulocytes were visualized using the Naphthol
AS-D Chloroacetate (specific esterase) kit (Sigma, 91C-1KT) according to the manufacturer’s instruc-
tion. Toluidine blue staining for mast cells was carried out as described (Mascia et al., 2013). Histol-
ogy images were acquired with a ZEISS microscope Imager M1 (20x/0.5 or 10x/0.3 Plan-NeoFluar
objectives) equipped with ZEISS AxioCamMRc5. Data were analyzed with ZEISS Axiovision Release
4.8.1 software (Carl Zeiss, Germany). Fluorescent images were acquired with ZEISS Axioplan2 micro-
scope (40x objective, Zeiss Plan – NEOFLUAR; Num: ap. 1.3) equipped with Spot Pursuit Camera
(Visitron Systems, Germany) and analyzed with VisiView software (Visitron Systems).
Blood analysis and FACS
Peripheral blood cell counts were acquired using V-Sight (Menarini Diagnostics, Italy). Spleen and
lymph node cells were stained with antibodies against CD11c (550261), CD4 (553051), MHC II
(557000), CD69 (557392), CD80 (553768), CD8 (553032), B220 (553090), Mac1 (553310) and Gr1
(553128) all from BD Bioscience and analyzed by FACSCalibur (BD Bioscience) and FlowJo V10 soft-
ware (Ashland, OR).
FlowCytomix analyte assay and ELISA
Cytokines and chemokines were detected in cell supernatants, serum samples and epidermal tissue
lysates using the Affymetrix eBioscience bead-based multiplex immunoassay. Data were analyzed
with FlowCytomix Pro2.4 software. GCSF (R&D Systems, DY414), TSLP (R&D Systems, DY555) and
IgEs (Bethyl Laboratories, E90-115) in serum samples were detected by ELISA according to the man-
ufacturer’s protocol.
Barrier function assays
Water loss assay and toluidine blue dye staining of embryos were carried out as described
(Tunggal et al., 2005).
Cell culture
HaCaT cells obtained from the DKFZ and mouse keratinocytes were maintained as described
(Doma et al, 2013). BRAF (L-003460-00), MLK3 (L-003577-00) and RAF1 (L-003601-00) were silenced
using ON-TARGETplus SMARTpool siRNAs (Thermo Fisher Scientific, Waltham, MA). Nontargeting
pool (D-001810-10-20) was used as control. In accordance with the supplier’s protocol, 5105 cells
were transfected with 25 nM of the previously mentioned oligos. Cells were treated with EGF (2 ng/
ml, R&D Systems, 2028-EG) and/or with TNFa (2.5 ng/ml, Millipore, Billerica, MA, 654245) and IL1b
(2.5 ng/ml, R&D Systems, 401-ML/CF) as indicated. For cytokine/chemokine assays supernatants
were collected 24 hr later. In selected experiments, cells were pretreated for 1 hr with medium con-
taining DMSO (for trametinib) or TAT peptide only (for D-JNKI1) or with the following inhibitors:
D-JNKI1 (2mM) or trametinib (5mM).
Lentiviral vectors, cloning and transduction procedure
Two independent shRNAs against mouse MLK3 (shRNA1, binding site 2266–2285 and shRNA2,
binding site 2383–2402) were designed as 97-bp oligomers containing a 20bp targeting sequence
embedded in a shRNAmir stem, amplified and cloned into Xho and EcoRI sites of the miRE lentiviral
recipient vector pRRL.SFFV.GFP.miRE.PGK.Puro (SGEP) (Fellmann et al., 2013). The SGEP plasmid
containing Renilla shRNA served as a control. Lentiviral vectors were transfected in 293T cells. Viral
supernatants were collected after 24 and 48 hr and passed through a 0.45-mm filter (Sarstedt, Ger-
many). Each fresh viral supernatant was used for primary keratinocyte spinfection (1500 g, 30 min).
Primary keratinocyte cultures were harvested 72 hr after first transduction.
Immunoblotting
Cell and epidermal lysates prepared as previously described (Doma et al., 2013) were immunoblot-
ted using the following primary antibodies (1:1000): TUBA (T9206,) from Sigma; pERK1/2 (9101),
ERK1/2 (9102), JNK1/2 (9258), pJNK 1/2 (9251), pJUN (9164), pMAPKAPK2 (3041), pp38 (9211), p38
(9212) and ICAM1 (4915) from Cell Signaling Technology; ACTB (sc-1616), 14-3-3 (sc-1657), BRAF
(sc-5284), RAF1 (sc-133) and MLK3 (sc-166639 and sc-536) from Santa Cruz Biotechnology (Dallas,
Raguz et al. eLife 2016;5:e14012. DOI: 10.7554/eLife.14012 19 of 23
Research article Immunology
TX); CDH1 (610181) from BD Biosciences; OCLN (ab31721), pRSK (ab32413), TSLP (ab188766) and
DUSP10 (ab140123) from Abcam; GAPDH (ABS16) and DUSP1 (07–535) from Millipore; ICAM1
(AF796, R&D Systems) and CLDN1 (374900, Invitrogen, Karlsbad, CA).
Quantitative PCR
RNA was isolated using Nucleospin RNA II kit (Macherey-Nagel, Germany). cDNA was prepared
using Oligo(dT)18 primer, dNTPs, and RevertAidReverse Transcriptase (Thermo Fisher Scientific).
qPCR was performed using Go Taq qPCR Master mix (A6002, Promega, Madison, WI). Relative
expression was calculated by the DDCT method using ACTB as housekeeping gene. Human CCL2
primers used: for 5‘-CAGCCAGATGCAATCAATGC-3´ and rev 5´-GCACTGAGATCTTCCTATTGG
TGAA-3´, human ACTB for 5‘-AGAGCTACGAGCTGCCTGAC-3´ and rev 5´-AGCACTGTGTTGGCG
TACAG-3´. Mouse Ccl2 primers used: for 5‘-CCCAATGAGTAGGCTGGAGA-3´ and 5‘-AAAATGGA
TCCACACCTTGC-3´; mouse Tslp for 5‘-CGACAGCATGGTTCTTCTCA-3´ and 5‘-CGATTTGC
TCGAACTTAGCC-3´, mouse ActB for 5‘-CCTCTATGCCAACACAGTGC-3´ and 5‘-GTACTCCTGC
TTGCTGATCC-3´.
Statistical analysis
Histological samples from at least three animals per condition and genotype were analyzed by
counting or measuring at least 3–5 microscopic field/section and analyzed by ImageJ software. Val-
ues are expressed as mean (±SEM). The number of biological replicates and, where applicable, tech-
nical replicates are indicated in the figure legends. p values were calculated using the two-tailed
Student’s t test, hetero- or homoskedastic as determined by a previous F-test of equality of varian-
ces or, when indicated, by two-way analysis of variance (ANOVA) test. A p value  0.05 is consid-
ered statistically significant.
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